Proteomedix receives IVDR certification for Proclarix®

Zurich-Schlieren, Switzerland, October 18, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that is has received IVDR certification for its prostate cancer diagnostic test  Proclarix® from TÜV SÜD. The new In Vitro Diagnostic Regulation (IVDR) recently replaced the IVD Directive. Under the IVDR, diagnostic products are...

read more